Abstract
AbstractCOVID-19 together with variants have caused an unprecedented amount of mental and economic turmoil with ever increasing fatality and no proven therapies in sight. The healthcare industry is racing to find a cure with multitude of clinical trials underway to access the efficacy of repurposed antivirals, however the much needed insights into the dynamics of pathogenesis of SARS-CoV-2 and corresponding pharmacology of antivirals are lacking. This paper introduces systematic pathological model learning of COVID-19 dynamics followed by derivative free optimization based multi objective drug rescheduling. The pathological model learnt from clinical data of severe COVID-19 patients treated with remdesivir could additionally predict immune T cells response and resulted in a dramatic reduction in remdesivir dose and schedule leading to lower toxicities, however maintaining a high virological efficacy.
Funder
University of Connecticut
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Planas, D. et al. Reduced sensitivity of sars-cov-2 variant delta to antibody neutralization. Nature 596, 276–280 (2021).
2. Dutta, A. Necessity of systems medicine, neuroscience outreach to combat covid-19. Ann. Neurol. 1, S112 (2020).
3. Menachery, V. D. et al. A sars-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508–1513 (2015).
4. Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
5. Risitano, A. M. et al. Complement as a target in covid-19?. Nat. Rev. Immunol. 20, 343–344 (2020).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献